TEDOPaM Prodige 63

A randomized non-comparative phase II study of Maintenance therapy with OSE2101 plus FOLFIRI, or FOLFIRI after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic Pancreatic ductal adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study).
  • Open at Saint-Cloud since : 11/02/2019
  • Target : Adult
  • Phase : Phase II

Trial description

TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination with FOLFIRI reintroduction, versus FOLFIRI as maintenance therapy in patients with advanced PDAC after induction therapy with FOLFIRINOX.
Url of the trial